Key points
- Full year sales of A$34.9 million, up 26% in constant currency
- Positive EBITDA of A$0.2 million in the first half of FY26
- Full year EBITDA loss improved by A$3.5 million from the prior year
- FY27 sales guidance reaffirmed
- Positive EBITDA expected in FY27
Full summary
Nova Eye Medical Ltd (ASX: EYE) reported its audited financial statements for the year ended 30 June 2026, showing full-year sales of A$34.9 million, a 26% increase in constant currency. The company achieved positive EBITDA of A$0.2 million in the first half of FY26, with a full-year EBITDA loss of A$2.0 million, an improvement of A$3.5 million from the prior year. Gross margin improved due to increased sales and declining manufacturing costs. The company reaffirmed its FY27 sales guidance, expecting sales (excluding China) to be between US$26 million and US$31 million, with a positive EBITDA expected.
Guidance
FY27 sales (excluding China) expected between US$26 million and US$31 million
Outlook
Nova Eye Medical Ltd expects to generate a positive EBITDA in FY27 and believes the growth outlook is strong.